CP3's Dr. Tim Anderson was a guest on the GeriPal podcast to discuss when to start or stop statins in older adults. Drawing on his role as the American Geriatrics Society representative on the 2026...
CP3 is proud to support a new Postdoctoral Research Fellowship in Optimizing Addiction Pharmacotherapy, offered through VA Pittsburgh Healthcare System in partnership with the University of Pittsburgh...
The University of Pittsburgh's General Internal Medicine fellowship applications are now open for programs starting July 2027. Deadline to apply is September 10th.
A study led by CP3's Tim Anderson on how the 2026 AHA/ACC dyslipidemia guideline expands statin eligibility for primary prevention has drawn wide national media coverage since its publication in JAMA...
New research from CP3's Tim Anderson, published today in JAMA, finds that more than half of U.S. adults ages 30 to 79 (about 87.5 million people) are now recommended for statins under updated...
CP3 faculty Lucas Berenbrok, PharmD, MS, FAPhA, Associate Professor and Director of the University of Pittsburgh School of Pharmacy CLIP Center, and collaborator Elaine Mormer, PhD (Department of...
This week the FDA approved Lipfendra (enlicitide), a once-daily pill and the first oral PCSK9 inhibitor for high cholesterol. CP3's Dr. Tim Anderson spoke with TribLIVE on what this means for patients...
Drs. Walid Gellad and Courtney Kuza were pleased to represent CP3 at the College on Problems of Drug Dependence (CPDD) Annual Scientific Conference in Portland, OR. Both took part in a mini-symposium...
CP3 always has a good showing at the Professional Society for Health Economics and Outcomes Research (ISPOR) annual conference, and this year was no exception. Not only did our machine learning expert...
